Skip Navigation

JNCI Journal of the National Cancer Institute 1999 91(24):2077-2078; doi:10.1093/jnci/91.24.2077
© 1999 by Oxford University Press
This Article
Right arrow Full Text Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Miller, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Miller, M.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Journal of the National Cancer Institute, Vol. 91, No. 24, 2077-2078, December 15, 1999
© 1999 Oxford University Press

NEWS

Taxing the Taxanes: Overused Or Undersold?

Mike Miller

Since taxanes were first touted as the anticancer drugs of the 1990s, their use has become widespread in both advanced breast and ovarian cancers as well as in clinical trials for other cancers.

At the most recent meeting of the Chemotherapy Foundation in New York, at least half of the chemotherapeutic interventions described against solid tumors used one kind of taxane or another. The current research paradigm is whether taxanes are . . . [Full Text of this Article]

Defining Mechanisms

Incremental Steps


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?